These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Two-Year Outcomes of Sacral Neuromodulation Versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: A Randomized Trial. Amundsen CL; Komesu YM; Chermansky C; Gregory WT; Myers DL; Honeycutt EF; Vasavada SP; Nguyen JN; Wilson TS; Harvie HS; Wallace D; Eur Urol; 2018 Jul; 74(1):66-73. PubMed ID: 29482936 [TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of sacral neuromodulation and botulinum toxin A treatment for patients with idiopathic overactive bladder. Leong RK; de Wachter SG; Joore MA; van Kerrebroeck PE BJU Int; 2011 Aug; 108(4):558-64. PubMed ID: 21166750 [TBL] [Abstract][Full Text] [Related]
6. Shifts in patient preference of third-line overactive bladder therapy after introduction of the implantable tibial nerve stimulator. Kapur A; Aalami Harandi A; Hartman-Kenzler J; Kim J Neurourol Urodyn; 2024 Apr; 43(4):959-966. PubMed ID: 38390786 [TBL] [Abstract][Full Text] [Related]
7. Sacral neuromodulation in patients with idiopathic overactive bladder after initial botulinum toxin therapy. Smits MA; Oerlemans D; Marcelissen TA; Van Kerrebroeck PE; De Wachter SG J Urol; 2013 Dec; 190(6):2148-52. PubMed ID: 23872028 [TBL] [Abstract][Full Text] [Related]
8. Urinary tract infection and drug-resistant urinary tract infection after intradetrusor onabotulinumtoxinA injection versus sacral neuromodulation. Elmer-Lyon CG; Streit JA; Takacs EB; Ten Eyck PP; Bradley CS Int Urogynecol J; 2020 May; 31(5):871-879. PubMed ID: 31222571 [TBL] [Abstract][Full Text] [Related]
9. Refractory overactive bladder patients who chose sacral neuromodulation therapy after failed OnabotulinumtoxinA treatment: A systematic review and meta-analysis. Yang G; Xu Y; Qu G; Zhang Y PLoS One; 2020; 15(3):e0230355. PubMed ID: 32226049 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerance of botulinum toxin injections after sacral nerve stimulation failure for idiopathic overactive bladder. Baron M; Perrouin-Verbe MA; Lacombe S; Paret F; Le Normand L; Cornu JN Neurourol Urodyn; 2020 Mar; 39(3):1012-1019. PubMed ID: 32108383 [TBL] [Abstract][Full Text] [Related]
11. Treatment for refractory overactive bladder: a systematic review and meta-analysis of sacral neuromodulation and onabotulinumtoxinA. He Q; Li B; Zhang C; Zhang J; Luo D; Wang K Int Urogynecol J; 2021 Mar; 32(3):477-484. PubMed ID: 32661556 [TBL] [Abstract][Full Text] [Related]
12. What uro-gynecologists should know about sacral neuromodulation (SNM) for the treatment of refractory overactive bladder. Oelke M; Addali M; Reisenauer C Arch Gynecol Obstet; 2019 May; 299(5):1243-1252. PubMed ID: 30941558 [TBL] [Abstract][Full Text] [Related]
13. Sacral neuromodulation in patients with refractory overactive bladder symptoms after failed Botulinum toxin therapy: Results in a large cohort of patients. Reekmans M; Janssen JMW; Vrijens DMJ; Smits MAC; van Koeveringe GA; Van Kerrebroeck PEVA Neurourol Urodyn; 2021 Jun; 40(5):1120-1125. PubMed ID: 33829519 [TBL] [Abstract][Full Text] [Related]
15. Botulinum toxin injections for adults with overactive bladder syndrome. Duthie JB; Vincent M; Herbison GP; Wilson DI; Wilson D Cochrane Database Syst Rev; 2011 Dec; (12):CD005493. PubMed ID: 22161392 [TBL] [Abstract][Full Text] [Related]
16. Sacral neuromodulation and Botulinum toxin A for refractory idiopathic overactive bladder: a cost-utility analysis in the perspective of Italian Healthcare System. Bertapelle MP; Vottero M; Popolo GD; Mencarini M; Ostardo E; Spinelli M; Giannantoni A; D'Ausilio A World J Urol; 2015 Aug; 33(8):1109-17. PubMed ID: 25218855 [TBL] [Abstract][Full Text] [Related]
17. Outcomes of sequential third-line therapies in patients with refractory overactive bladder. Chow PM; Trump T; Goldman HB Int J Urol; 2024 Jul; 31(7):772-777. PubMed ID: 38693892 [TBL] [Abstract][Full Text] [Related]
18. Mechanism and Priority of Botulinum Neurotoxin A versus Sacral Neuromodulation for Refractory Overactive Bladder: A Review. Zhang Y; Ji F; Liu E; Wen JG Urol Int; 2021; 105(11-12):929-934. PubMed ID: 34130295 [TBL] [Abstract][Full Text] [Related]
19. A comparative study between sacral neuromodulation and intravesical botulinum toxin injection for patients with refractory overactive bladder. Al-Azzawi IS; Al-Hindawi HT Arab J Urol; 2020 Mar; 18(2):88-93. PubMed ID: 33029412 [TBL] [Abstract][Full Text] [Related]
20. What Is the Role of Additional Pharmacotherapy and Neuromodulation in Patients with Marginal Benefit from Botulinum Toxin Injection? Zahner PM; Giusto LL; Goldman HB Curr Urol Rep; 2018 Sep; 19(11):91. PubMed ID: 30196438 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]